Skip to content
Triangle logo TriangleGet started
← Study library

NCT00931528 · CITED IN SOURCE DOCUMENTS

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2018-02-14

RATIONALE: Tadalafil may help prevent erectile dysfunction (ED) in patients with prostate cancer that has been treated with radiation therapy. It is not yet known whether tadalafil is more effective than a placebo in preventing erectile dysfunction. PURPOSE: This randomized phase III trial is studying tadalafil to see how well it works compared with a placebo in preventing erectile dysfunction in patients with prostate cancer treated with radiation therapy.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Percentage of Patients Maintaining Spontaneous (Off-drug) Erectile Function (EF) at Weeks 28-30 After Initiation of Radiation Therapy (RT)

→

outcome · POSTED

Percentage of Patients Maintaining Spontaneous (Off-drug) EF at Years 1 and 2 After Initiation of RT

→

outcome · POSTED

Overall Sexual Function as Measured by Change From Baseline in the International Index of Erectile Function (IIEF)

→

outcome · POSTED

Overall Patient Sexual Satisfaction as Measured by Change From Baseline in the Sexual Adjustment Questionnaire (SAQ) Score

→

outcome · POSTED

Overall Partner Sexual Satisfaction as Measured by Change From Baseline in the Sexual Adjustment Questionnaire-Partner (SAQ-P) Score

→

outcome · POSTED

Patient Marital Adjustment as Measured by the Locke's Marital Adjustment Test

→

outcome · POSTED

Partner Marital Adjustment as Measured by the Locke's Marital Adjustment Test

→

outcome · NOT POSTED

Radiotherapy Factors Associated With Spontaneous (Off-drug) EF at Weeks 28-30 and Years 1 and 2 After Initiation of RT

→

outcome · NOT POSTED

Patient Follow-up Treatment for Erectile Dysfunction at Weeks 28-30 and Years 1 and 2 After Initiation of RT

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: 1. Clinical stage T1b-T2b (AJCC, 6th ed.) adenocarcinoma of the prostate within 6 months of registration 2. Clinically negative lymph nodes as established by imaging (pelvic ± abdominal CT or MR), nodal sampling, or dissection within 3 months prior to registration. Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are ≤ 1.5 cm. Lymph node assessment is optional, and at investigator discretion, for patients with Gleason Score \<7. 3. No evidence of bone metastases (M0) on bone scan within 3 months prior to registration. Equivocal bone scan findings are allowed if plain films are negative for metastasis. Bone metastases assessment is optional, and at investigator discretion, for patients with Gleason Score \<7. 4. Baseline serum prostatic specific antigen (PSA) value performed with an FDA-approved assay (e.g., Abbott, Hybritech) within 3 months prior to registration. -4.1 Any of the following combinations of factors (NOTE: tumor found in 1 or both lobes on biopsy, but not palpable, will not alter T stage): * T1b-T2b disease, Gleason Score \<7 and serum total PSA that is \<20 ng/ml or * T1b-T2b disease, Gleason Score ≥7 and PSA that is \<15 ng/ml 5. Serum total testosterone level prior to the initiation of radiation therapy (RT) within normal range according to institutional guidelines 6. Zubrod Performance Status 0 or 1 (Appendix III) 7. Age ≥ 18 years 8. Treatment that will consist of either external beam RT alone to the prostate ± seminal vesicles only at a dose between 75 Gy and 79.2 Gy or brachytherapy alone (NOTE: treatment with combined external RT and brachytherapy excludes patient participation) 9. Pretreatment (before starting prostate cancer treatment) erectile function as measured by IIEF Question 1, "How often were you able to get an erection during sexual activity?" - with responses of: * "sometimes (about half the time)" \[response 3\] or * "most times (much more than half the time)" \[response 4\] or * "almost always/always" \[response 5\] 10. History of prior tadalafil use: Document usual dosage per sexual encounter, date of last dose, and patient's response (No; Yes-Unsatisfactory Response; Yes-Satisfactory Response). Regardless of past experience, the patient is eligible if he agrees to adhere to protocol and take only tadalafil or placebo prescribed on study. 11. Although patients with partners are targeted for recruitment, patients without partners or without partners willing to participate are eligible. Patients (and spouses/partners, if willing to participate) must be able to provide study-specific informed consent. Exclusion Criteria: 1. The patient's participation in another medical research study that involves the treatment of ED 2. Previous or concomitant invasive cancer (American Joint Committee on Cancer \[AJCC\] Stage \>0), other than localized basal cell or squamous cell skin carcinoma (AJCC Stage 0-II), or a hematological malignancy (e.g., leukemia, lymphoma, myeloma) unless continually disease free for at least 5 years 3. History of myocardial infarction within the last year 4. Heart failure in the last 6 months 5. Uncontrolled arrhythmias, hypotension (\<90/50mm Hg), or uncontrolled hypertension (\>170/100 mm Hg) 6. Stroke within the last 6 months 7. Use of luteinizing hormone-releasing hormone (LHRH) agonist androgen suppression (e.g., Lupron, Zoladex), anti-androgen (e.g., Casodex, Eulexin, Nilandron), or estrogenic (e.g., diethylstilbestrol) agents within the last 6 months 8. Current use of any organic nitrate or as needed nitrates (e.g., use of nitroglycerin) 9. Current use of cimetidine, ketoconazole, itraconazole, erythromycin, or ritonavir 10. Known moderate to severe renal insufficiency or end-stage renal disease 11. Known severe hepatic impairment 12. Use of mechanical (vacuum) devices, intracorporeal, intraurethral, topical, or oral (sildenafil, tadalafil, vardenafil) agents as therapy for ED or supplements to enhance sexual function within 5-7 days prior to the start of RT. Patients who discontinue these therapies remain eligible if they can meet eligibility criteria 13. Pretreatment (before starting prostate cancer treatment) ED as measured by IIEF Question 1, "How often were you able to get an erection during sexual activity?" - with responses of: * "no sexual activity" \[response 0\] or * "almost never/never" \[response 1\] or * "a few times (much less than half the time)" \[response 2\] 14. Prior penile implant or history of bilateral orchiectomy 15. Prior prostatectomy, prostatic cryosurgery or high-intensity focused ultrasound (HIFU), radionuclide prostate brachytherapy, or chemotherapy for prostate cancer 16. Prior or anticipated combined external RT and brachytherapy 17. Prior or anticipated external RT to the pelvic ± para-aortic lymph nodes 18. Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. Protocol-specific requirements may also exclude immunocompromised patients. 19. Anatomical genital abnormalities or concurrent conditions that in the estimation of the physician would prohibit sexual intercourse or prevent study completion 20. Major medical or psychiatric illness which, in the opinion of the investigator, would prevent completion of treatment or would interfere with follow-up
healthy Volunteers
true
maximum Age
120 Years
minimum Age
18 Years
sex
MALE
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Tadalafil
    intervention Names
    1. Drug: Tadalafil
    label
    Tadalafil
    type
    EXPERIMENTAL
  2. description
    Placebo
    intervention Names
    1. Other: Placebo
    label
    Placebo
    type
    PLACEBO_COMPARATOR
interventions
  1. arm Group Labels
    1. Tadalafil
    description
    Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.
    name
    Tadalafil
    type
    DRUG
  2. arm Group Labels
    1. Placebo
    description
    Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.
    name
    Placebo
    type
    OTHER
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
TRIPLE
who Masked
  1. PARTICIPANT
  2. INVESTIGATOR
  3. OUTCOMES_ASSESSOR
primary Purpose
SUPPORTIVE_CARE
Enrollment
count
242
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. measure
    Radiotherapy Factors Associated With Spontaneous (Off-drug) EF at Weeks 28-30 and Years 1 and 2 After Initiation of RT
    time Frame
    Baseline, week 30 and years 1 and 2 after the start of treatment
  2. measure
    Patient Follow-up Treatment for Erectile Dysfunction at Weeks 28-30 and Years 1 and 2 After Initiation of RT
    time Frame
    Baseline, week 30 and years 1 and 2 after the start of treatment
primary Outcomes
  1. description
    EF is measured by Question 1 of the International Index of Erectile Function (IIEF). The IIEF is a validated 15-item for measuring patient-reported erectile function. Question 1 asks "How often were you able to get an erection during sexual activity?" Responses ranged from 0=no sexual activity, to 5=Almost always or always. Higher scores indicated better functioning. All patients have erectile function prior to initiation of RT, indicated by a score of 3, 4, or 5 on IIEF Q1. Patients with a lower IIEF Q1 score at weeks 28-30 than at baseline will have less erectile function and be categorized as nonresponders. Patients with similar or improved erectile function will be categorized as responders (maintaining). Patient-related predictors of at erectile function at this time point are also reported with this outcome measure.
    measure
    Percentage of Patients Maintaining Spontaneous (Off-drug) Erectile Function (EF) at Weeks 28-30 After Initiation of Radiation Therapy (RT)
    time Frame
    Baseline and 30 weeks from the start of radiation therapy
secondary Outcomes
  1. description
    The International Index of Erectile Function (IIEF) is a validated 15-item for measuring patient-reported erectile function. Question 1 asks "How often were you able to get an erection during sexual activity?" Responses ranged from 0=no sexual activity, to 5=Almost always or always. Higher scores indicated better functioning. All patients have erectile function prior to initiation of RT, indicated by a score of 3, 4, or 5. Patients with a lower IIEF Q1 score at weeks 28-30 than at baseline will have less erectile function and be categorized as nonresponders. Patients with similar or improved erectile function will be categorized as responders (maintaining). Patient-related predictors of at erectile function at Years 1 and 2 are also reported with this outcome measure.
    measure
    Percentage of Patients Maintaining Spontaneous (Off-drug) EF at Years 1 and 2 After Initiation of RT
    time Frame
    Baseline, 1 and 2 years from the start of tadalafil or placebo
  2. description
    The IIEF is a validated 15-item for measuring patient-reported erectile function. A score of 0-5 is given to each of the 15 questions that examine 5 main domains of male sexual function: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. Domain scores are the sum of each item. The erectile function domain has 5 items with a score range of 1-30, orgasmic function has 2 items with a score range of 0-10, sexual desire has 2 items with a score range of 0-10, intercourse satisfaction has 3 items with a score range of 0-15, and overall satisfaction has 2 items with a score range of 2-10. Total score ranges from 0-70, with higher scores indicated better functioning. Change from baseline is calculated by subtracting baseline score from score at the time point of interest.
    measure
    Overall Sexual Function as Measured by Change From Baseline in the International Index of Erectile Function (IIEF)
    time Frame
    Baseline, week 30, and years 1 and 2 from start of treatment
  3. description
    The Sexual Adjustment Questionnaire (SAQ) is a 20-item questionnaire with an overall score range between 8 and 100 including the following domains: desire, ranging between 5 and 30; dysfunction, 0 and 25; activity, 0 and 10; satisfaction, 1 and 10; and fatigue, 1 and 5. The change in SAQ score is calculated by subtracting the baseline score from the follow-up score. A positive change indicates an improvement in sexual well-being.
    measure
    Overall Patient Sexual Satisfaction as Measured by Change From Baseline in the Sexual Adjustment Questionnaire (SAQ) Score
    time Frame
    Baseline, week 30 and years 1 and 2 after the start of treatment
  4. description
    The SAQ-P is an 18-item questionnaire with an overall score range between 0 and 90 including the following domains: desire, dysfunction, activity, satisfaction, and fatigue. The change in SAQ score is calculated by subtracting the baseline score from the follow-up score. A positive change indicates an improvement in sexual well-being.
    measure
    Overall Partner Sexual Satisfaction as Measured by Change From Baseline in the Sexual Adjustment Questionnaire-Partner (SAQ-P) Score
    time Frame
    Baseline, week 30 and years 1 and 2 after the start of treatment
  5. description
    The Locke Marital Adjustment Test (LMAT) is a 16-item questionnaire with scores ranging from 48 to 138 for participants. Higher scores indicate greater sexual function, sexual wellbeing, or marital adjustment. The change in LMAT score is calculated by subtracting the baseline score from the follow-up score.
    measure
    Patient Marital Adjustment as Measured by the Locke's Marital Adjustment Test
    time Frame
    Baseline, week 30 and years 1 and 2 after the start of treatment
  6. description
    The Locke Marital Adjustment Test (LMAT) is a 16-item questionnaire with scores ranging from 48 to 138 for participants. Higher scores indicate greater sexual function, sexual wellbeing, or marital adjustment. The change in LMAT score is calculated by subtracting the baseline score from the follow-up score.
    measure
    Partner Marital Adjustment as Measured by the Locke's Marital Adjustment Test
    time Frame
    Baseline, week 30 and years 1 and 2 after the start of treatment
Full study description
brief Summary
RATIONALE: Tadalafil may help prevent erectile dysfunction (ED) in patients with prostate cancer that has been treated with radiation therapy. It is not yet known whether tadalafil is more effective than a placebo in preventing erectile dysfunction. PURPOSE: This randomized phase III trial is studying tadalafil to see how well it works compared with a placebo in preventing erectile dysfunction in patients with prostate cancer treated with radiation therapy.
detailed Description
OBJECTIVES: Primary * To determine whether tadalafil maintains spontaneous (off-drug) erectile function, as measured by the International Index of Erectile Function (IIEF) as compared to placebo at weeks 28-30 after initiation of radiotherapy in patients with prostate cancer. Secondary * Determine the difference in spontaneous (off-drug) erectile function between tadalafil and placebo at 1 and 2 years. * Determine the difference in overall sexual function as measured by the IIEF between tadalafil and placebo at weeks 28-30 and at 1 and 2 years. * Determine differences in patient and partner overall sexual satisfaction as measured by the Sexual Adjustment Questionnaire (SAQ) between tadalafil and placebo at weeks 28-30 and at 1 and 2 years. * Determine differences in patient and partner marital adjustment as measured by Locke's Marital Adjustment Test (LMAT) between tadalafil and placebo at weeks 28-30 and at 1 and 2 years. * Determine associations between patient and partner overall sexual satisfaction as measured by SAQ and patient and partner marital adjustment as measured by LMAT at weeks 28-30 and at 1 and 2 years. * Determine patient-related factors (i.e., age, pretreatment sexual response, tobacco use, and comorbidities) that may predict response to tadalafil therapy at weeks 28-30 and at 1 and 2 years. * Determine the difference in adverse events between tadalafil and placebo as assessed by Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 criteria. Tertiary * Characterization of preference and erectile function among patients who choose to stay on (or if on placebo, to start) tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor other than tadalafil, a non-PDE5-inhibitor erectile aide, or no PDE5 inhibitor or erectile aide at 28-30 weeks and at 1 and 2 years. * Identification of radiotherapy factors (i.e., modality, prescribed total dose, planning target volume margin, penile bulb dose-volume parameters) associated with erectile function. * Evaluation of the number of patients screened for eligibility, the number eligible that are presented the study, the number who refuse, and the number who are accrued. OUTLINE: This is a multicenter study. Patients are stratified according to age (≤ 65 years vs \> 65 years) and radiotherapy treatment (external beam radiation therapy vs brachytherapy\*). Patients are randomized to 1 of 2 treatment arms. Note: \* Radiotherapy start date for brachytherapy patients is the date of the procedure. All patients undergo either external beam radiotherapy alone to the prostate ± seminal vesicles only or low-dose rate permanent brachytherapy alone. * Arm I: Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil once daily for 24 weeks in the absence of disease progression or unacceptable toxicity. * Arm II: Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients complete the International Index of Erectile Function (IIEF), the Sexual Adjustment Questionnaire (SAQ), the Locke's Marital Adjustment Test (LMAT) (if applicable), and the Expanded Prostate Cancer Index Composite Sexual Medications and Devices Evaluations Supplement questionnaires periodically. Partners or spouses complete the SAQ-Partner, LMAT (if applicable), and IIEF questionnaires periodically. After completion of study treatment, patients are followed at 28-30 weeks, and annually for up to 2 years.
Source references
references
  1. citation
    Pisansky TM, Pugh SL, Greenberg RE, Pervez N, Reed DR, Rosenthal SA, Mowat RB, Raben A, Buyyounouski MK, Kachnic LA, Bruner DW. Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial. JAMA. 2014 Apr 2;311(13):1300-7. doi: 10.1001/jama.2014.2626.
    pmid
    24691606
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-b6259ab7db52b3a3e511
      requested nct id
      NCT00931528
      primary nct id
      NCT00931528
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      89c3cbcb10a3e14c5ee4b607046c929e5902a798e71e758f8a712b0ae71413cf
      payload sha256
      2c017509ff2622fa96608442d937c98aa6fa788da503df791ed207962294a348
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-b6259ab7db52b3a3e511
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00931528
      occurrences
      1. context exact
        000810021&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence A3</a>]</li><li>A randomized trial (<a href="/clinicaltrials/NCT00931528">RTOG-0831</a> [NCT00931528]) of 121 men with intact erectile function compared daily preventive tadalafil (5 mg PO qd) with placebo for 24 weeks beginning at
        end
        190170
        exact text
        NCT00931528
        start
        190159
      2. context exact
        Professional&amp;language=English'); return(false);">Level of evidence A3</a>]</li><li>A randomized trial (<a href="/clinicaltrials/NCT00931528">RTOG-0831</a> [NCT00931528]) of 121 men with intact erectile function compared daily preventive tadalafil (5 mg PO qd) with placebo for 24 weeks beginning at the start of either EBRT or
        end
        190198
        exact text
        NCT00931528
        start
        190187
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/48a3f061dd2bbd22e8.html
      source file sha256
      89c3cbcb10a3e14c5ee4b607046c929e5902a798e71e758f8a712b0ae71413cf
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:22:14.334045+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      351f45145a6c8591cdadd072763243033f8e1fa33cafecd55e4bac86e2b9edf3
      source title
      Prostate Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 14, 2025
        datetime
        2025-05-14T12:00:00Z
        display
        May 14, 2025

    Preserved source evidence · Not medical advice